United States · FDA National Drug Code directory
Rivaroxaban
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 67877-882_d111f8d6-a073-4a43-bf16-bc1bacba9898
- Product NDC
- 67877-882
- Form
- GRANULE, FOR SUSPENSION
- Composition / generic term
- Rivaroxaban
- Labeler
- Ascend Laboratories, LLC
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20250707
- Source listing expiry
- 20261231
Source-listed ingredients
- RIVAROXABAN — 155 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 BOTTLE in 1 CARTON (67877-882-71) / 1 GRANULE, FOR SUSPENSION in 1 BOTTLE · 67877-882-71
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →